Suchergebnisse - "Hanley, Michael J"

PubPharm (11)

1

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Hanley, M. | Yeo, K. | Tugnait, M. | +5

2

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and translational science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

3

Clinical Pharmacology of Brigatinib : A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

enthalten in: Clinical pharmacokinetics | 2023

von Gupta, N. | Hanley, M. | Griffin, R. | +3

4

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

enthalten in: Investigational new drugs | 2023

von Hanley, M. | Kerstein, D. | Tugnait, M. | +4

5

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

enthalten in: Journal of clinical pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

6

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions : Exposure-Response Analyses of a Pivotal Phase I/II Study

enthalten in: Clinical pharmacology and therapeutics | 2022

von Gupta, N. | Largajolli, A. | Witjes, H. | +5

7

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: British journal of clinical pharmacology | 2022

von Gupta, N. | Hanley, M. | Sinha, V.

CommentOn: Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. - PMID 34545619

8

Population pharmacokinetic and exposure-response analyses from ALTA-1L : Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC

enthalten in: Clinical and translational science | 2022

von Gupta, N. | Reckamp, K. | Camidge, D. | +8

9

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

10

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer : Second Interim Analysis of the Phase III ALTA-1L Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Camidge, D. | Kim, H. | Ahn, M. | +19

CommentIn: J Clin Oncol. 2020 Nov 1;38(31):3581-3583. - PMID 32897826